Janus Henderson Investors — Full Portfolio
60 tracked investments · listed companies and verified rows first
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Chief Executive Officer, President, and Co-Founder)inDavid Schaffer(Director)inTheresa Janke(Chief of Staff, Co-Founder)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesPappas CapitalPfizer Venture Investments+7 more
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundPappas CapitalRA Capital+5 more
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore Capital+8 more
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed+7 more
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investors5AM VenturesOrbiMedPfizer Venture InvestmentsRoche Venture FundARCH Venture PartnersBay City Capital+2 more
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder.
BiotechHealthtechMedical DevicesLake Forest, US
Chandler D. Robinson(Executive Officer, Director, Promoter)inChristopher M. Starr(Executive Officer, Director)Andrew P. Mazar(Executive Officer, Director)
BoardMichael J. Brown(Director)
Co-investorsRA Capital
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)+9 more
Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies.
BiotechDeep TechHealthtechVenice, US
Lawrence Steinman(Director)Tiago Reis Marques(Chief Executive Officer)inIsrael Maxx Abramowitz(Executive Officer, Director)Craig Auringer(Executive Officer, Director)
Co-investorsVivo Capital
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalOrbiMedRA Capital+2 more
Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.
BiotechDeep TechHealthtechSouth San Francisco, US
Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Co-investorsAbingworthCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesLongitude CapitalMedicxi+4 more
Vaxcyte is a clinical-stage biotechnology company developing vaccines to prevent or treat bacterial infectious diseases, including pneumococcal conjugate vaccine candidates.
BiotechHealthtech
Grant Pickering(Chief Executive Officer, Director and Co-Founder)inJeff Fairman(Vice President of Research and Co-Founder)
Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesLongitude CapitalPivotal Life Sciences+3 more
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCrystal MacKay(Chief Operating Officer)in
Co-investorsINCE CapitalRA CapitalSalviaBiotechnology Value FundREDMILE
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.
BiotechHealthtech
Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)
Co-investorsAtlas VentureLAVvenBio PartnersWellington Management
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.
BiotechHealthtechMedical DevicesSuzhou, CN
Co-investorsLAVLilly Asia VenturesOrbiMedPivotal Life SciencesExome Asset ManagementRA Capital+3 more
35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need.
BiotechHealthtech
Ilia(CEO)Maureen(CSO)
Co-investorsFrazier Life SciencesvenBio PartnersVivo Capital
AgelessRx offers prescription weight management medications delivered through a telehealth platform, including GLP-1 medications (semaglutide, tirzepatide), FDA-approved weight loss drugs (Wegovy, Zepbound), and supportive treatments like metformin and vitamin injections for adults seeking medically-supervised weight loss.
BiotechDigital HealthDirect to ConsumerHealthtechLongevityAnn Arbor, US
Anar Isman(Co-Founder & Chief Executive Officer)inRobert Michael Pejovich(Director of Finance of the Issuer)
Co-investors1/1 Capitalabrdn plcAngelini VenturesFidelity InvestmentsSanofi Ventures
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
Ambros Therapeutics is a therapeutics company.
BiotechHealthtechSan Diego, US
Joseph (Jay) Hagan(President and Chief Executive Officer)
Co-investorsLifeSci Venture PartnersRA CapitalBAM ElevatePatient Square Capital
Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.
BiotechSouth San Francisco, US
Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalViking GlobalBlackRockCasdin Capital+6 more
Annexon is a clinical-stage biopharmaceutical company developing C1q and classical complement pathway inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.
BiotechHealthtechMedical DevicesSo. San Francisco, US
Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)
Co-investorsBain Capital Life SciencesCorrelation VenturesNew Enterprise Associates (NEA)BlackRockBlackstone Life SciencesClarus Ventures+2 more
Apartment List operates an online rental marketplace that uses a quiz-based AI matching system to connect renters with apartments that fit their preferences and lifestyle.
AI & Machine LearningMarketplacesPropTechSan Francisco, US
John Douglas Kobs II(Executive Officer, Director)Charles Christopher Herndon(Executive Officer, Director)John Kobs(Founder)inChris Erickson(Founder)in
BoardJosh Hannah(Director)Dana Stalder(Director)in
Co-investorsAndre IguodalaAUTHENTIC VENTURESCanaan PartnersGlynn Capital ManagementMatrixRealization Capital Partners+7 more
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupRevelation Partners+4 more
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsRA Capital+6 more
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Drug discovery)inYik Andy Yeung(Executive Officer, Director, Promoter)
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalWellington Management+9 more
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Co-investorsAlpha Wave GlobalBioBritLifeSci Venture PartnersvenBio PartnersREDMILESamsara BioCapital+2 more
Bigfoot Biomedical develops a diabetes management system that combines continuous glucose monitor data with a doctor's instructions to give insulin dose recommendations.
Digital HealthHealthtechMedical DevicesNew York, US
Jeffrey Brewer(Executive Officer, Director)inBryan Mazlish(Executive Officer, Director)inJon Brilliant(Executive Officer)
Co-investorsJDRF T1D FundWinklevoss CapitalXplorer CapitalSmile GroupVisionnaire Ventures, Llc
Calyxo develops medical devices for kidney stone removal, specifically a minimally invasive CVAC (Cavitation-Enabled Ablation and Clearance) system that has been FDA-cleared.
HealthtechMedical DevicesPleasanton, US
Chris Buchko(Executive Officer)inDouglas Hughes(Executive Officer, Director)Jee Shin(Executive Officer, Director)inMark Kidd(Executive Officer)Joe Catanese(Executive Officer, Director)
BoardRyan Drant(Director)in
Co-investorsQuesta CapitalAlly Bridge Group
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureSamsara BioCapitalWellington ManagementAlly Bridge GroupPerceptive Xontogeny Venture+1 more
Crypto.com operates a cryptocurrency exchange and digital asset platform serving 150 million users across 90 countries, with a mission to accelerate global adoption of cryptocurrency.
Crypto & Web3Fintech
Kris Marszalek(Co-Founder & CEO)inRafael Melo(Co-Founder & CFO)inBobby Bao(Co-Founder, Head of Crypto.com Capital)
Co-investorsMoonhill CapitalAvalanche FoundationBalderton CapitalBlockchain CapitalBNP ParibasBpifrance+10 more
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtech
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalOrbiMedRA CapitalSanofi VenturesHBM Healthcare InvestmentsMedicxi
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesLightstone VenturesOUP (Osage University Partners)Shah Family OfficeAlly Bridge GroupDe Novo Ventures+3 more
Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.
BiotechDeep TechDigital HealthMedical DevicesCardiff, GB
John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in
Co-investorsAccess BiotechnologyCanaan PartnersSanofi VenturesSV Health InvestorsSR One Capital ManagementBritish Business Bank
The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.
BiotechHealthtechSan Diego, US
Arthur Suckow, Ph.D.(Founder)in
Co-investorsAccess BiotechnologyExSight VenturesRA Capital
Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
Lei Stanley Qi(Scientific Founder)inAmber Salzman(Executive Officer, Director)inHaorui Zhang(Executive Officer, Director)
BoardAndrew Lam(Director)Anran Li(Director)Jennifer King(Director)
Co-investorsAlly Bridge Groupabrdn plcAngelini VenturesFidelity InvestmentsSanofi Ventures
Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.
AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US
Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)in
BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)
Co-investorsSofinnova PartnersTeamworthy VenturesThe Colorado Impact FundVTF CapitalAlly Bridge GroupCatalyst Investors+5 more
Galvanize Climate Solutions is an investment firm focused on the energy transition, deploying capital across areas such as climate risk analytics and clean energy.
CleantechClimate TechEnergy
Veery Maxwell(Founder)in
Co-investorsABS Capital PartnersBlue Haven InitiativeGalvanize Climate SolutionsAlly Bridge GroupFidelity InvestmentsGilmartin Capital LLC+4 more
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.
BiotechHealthtechMedical DevicesRedwood City, US
Doug Godshall(Executive Officer, Director)inSteve Anheier(Executive Officer)in
BoardJonathan Waldstreicher(Executive Officer)Antoine Papiernik(Director)inSeth Harrison(Director)Zack Scott(Director)in
Co-investorsNorwest Venture PartnersAlly Bridge GroupATPFidelity InvestmentsGilmartin Capital LLCPerceptive Xontogeny Venture+2 more
IntelyCare operates a healthcare talent marketplace that connects nurses with care settings including hospitals, clinics, and other healthcare facilities.
B2B MarketplacesFuture of WorkHealthtechHR TechQuincy, US
Ike Nnah(Executive Officer, Director)inDavid Coppins(Executive Officer, Director)inPrince Nnah(Director)
Co-investorsEastward Capital PartnersEndeavour VisionEquitage Ventures, L.L.C.First Trust Capital PartnersGenerator VenturesKaiser Permanente Ventures+4 more
Interleukin operates a B2B platform for sourcing and procuring medical products and services, letting registered buyers discover accredited suppliers, request quotes, send purchase orders, and pay on terms in one system.
B2B MarketplacesHealthtechMedical Devices
Co-investorsBuko VenturesDeerfield Management Company
Kardium develops the Globe Pulsed Field System, an all-in-one cardiac ablation catheter with 122 individually selectable electrodes that combines high-density mapping and pulsed field ablation.
BiotechHardwareHealthtechMedical DevicesBurnaby
Doug Goertzen(Executive Officer)inKevin Chaplin(Executive Officer, Director)in
BoardManuel Alba-Marquez(Director)Ian Ihnatowycz(Director)Armos Michelson(Director)David Rosa(Director)
Co-investorsEckuityGranada FundsRBCxFidelity InvestmentsQatar Investment Authority
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)
BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)in
Co-investorsForesite CapitalNextech InvestViking GlobalRA CapitalVenrock Healthcare Capital PartnersViking Global Investors
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsHBM PartnersBAM ElevateFranklin Templeton+5 more
Magnolia Medical develops diagnostic devices to reduce blood culture contamination and false-positive sepsis test results for hospitals and healthcare systems.
HardwareHealthtechMedical DevicesSeattle, US
Gregory J Bullington(Executive Officer, Director)Richard Patton(Co-founder)
BoardPaul Meister(Director)
Co-investorsEvidity Health CapitalLauder PartnersMarram VenturesRhapsody Venture PartnersVivo CapitalHealthQuest Capital+3 more
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.
BiotechHealthtechMedical DevicesNew York, US
Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)Clive Meanwell(Founder)
Co-investorsAlpha Wave GlobalARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision Fund+5 more
HealthtechWest Lafayette, US
Philip Low, Ph.D.(Director)Sunil Singhal, M.D.(Director)Isaac Barchas(Director)Clay B. Siegall, Ph.D.(Executive Officer, Director)Ronald Martell(Director)inFranklyn Prendergast, M.D., Ph.D.(Director)
Co-investorsEcoR1 CapitalArsenal Bridge VentureREDMILE
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsAtlas VentureNewpath Partners5AM VenturesARCH Venture PartnersDCVC (Data Collective)F-Prime Capital+11 more
Parse.ly is a content analytics and audience intelligence platform offering a real-time dashboard, a content recommendation API, a data pipeline to warehouses, and AI-driven insights.
Data & InfrastructureMarketing TechMedia & EntertainmentNew York, US
Sachin Kamdar(Executive Officer, Director, Promoter)inAndrew Montalenti(Executive Officer, Director, Promoter)in
BoardSteve Fredrick(Executive Officer, Director)Chris Gottschalk(Executive Officer, Director)
Co-investorsBlumberg CapitalFf Venture CapitalFundersClubHaatchHorizon Technology FinanceSahsen Ventures+2 more
BiotechFremont, US
Avanish Vellanki(Executive Officer)in
Co-investorsBiotechnology Value FundSamsara BioCapital
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesViking Global+11 more
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalThe Column GroupBain Capital Life SciencesCanaan PartnersRA CapitalTCG Crossover+2 more
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Co-investorsAscenta CapitalAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMed+4 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Founder)inAndrew Bellinger(Executive Officer)Kiran Musunuru(Founder)
BoardJohn Evans(Director)Anthony Philippakis(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalvenBio PartnersWellington Management+3 more
Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.
AI & Machine LearningData & InfrastructureDefense TechTel Aviv
Amiad Daniel(Executive Officer, Director)Matan Peled(Founder)inAmi Daniel(Founder)
BoardDov Gatmon(Director)Patrick Poon(Director)Eden Shochat(Director)in
Co-investorsAlephFTV CapitalThompson Hutton, LLCPivotal Life SciencesQiming Venture PartnersQuan Capital+3 more
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedQuan CapitalRA CapitalSanofi VenturesSR One Capital ManagementNovo Holdings+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Caldera Therapeutics, Inc.iTeos TherapeuticsRay TherapeuticsShoreline BiosciencesValenzaBio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.








































.png)


















































































































































































